Démarche clinique devant une hyperferritinémie

Deugnier, 2009, Hyperferritinémies non hémochromatosiques, Gastroenterol Clin Biol, 33, 323, 10.1016/j.gcb.2009.02.009 Gandon, 2004, Non-invasive assessment of hepatic iron stores by MRI, Lancet, 363, 357, 10.1016/S0140-6736(04)15436-6 Prise en charge de l’hémochromatose liée au gène HFE (hémochromatose de type 1) - Recommandations de l’HAS (juillet 2005). http://www.has-sante.fr/portail/upload/docs/application/pdf/recos_hfe-1_-_finale.pdf. 2010, EASL Clinical Practice Guidelines: HFE hemochromatosis, J Hepatol, 53, 3, 10.1016/j.jhep.2010.03.001 Brissot, 2011, Iron disorders of genetic origin: a changing world, Trends Mol Med, 17, 707, 10.1016/j.molmed.2011.07.004 Andrews, 2012, Closing the iron gate, N Engl J Med, 366, 376, 10.1056/NEJMcibr1112780 Fleming, 2012, Iron overload in human disease, N Engl J Med, 366, 348, 10.1056/NEJMra1004967 Mayr, 2010, Ferroportin disease: a systematic meta-analysis of clinical and molecular findings, J Hepatol, 53, 941, 10.1016/j.jhep.2010.05.016 Adams, 2011, A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation, J Hepatol, 55, 453, 10.1016/j.jhep.2011.02.010 Ratziu, 2010, A position statement on NAFLD/NASH based on the EASL 2009 special conference, J Hepatol, 53, 372, 10.1016/j.jhep.2010.04.008 Lainé, 2008, Hépatosidérose dysmétabolique : saigner ou ne pas saigner, Gastroenterol Clin Biol, 32, 421, 10.1016/j.gcb.2008.02.008 Guillygomarc’h, 2001, Venesection therapy of insulin resistance-associated hepatic iron overload, J Hepatol, 35, 344, 10.1016/S0168-8278(01)00147-7 Dongiovanni, 2011, Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target, J Hepatol, 55, 920, 10.1016/j.jhep.2011.05.008 Facchini, 2002, Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease, Gastroenterology, 122, 931, 10.1053/gast.2002.32403 Fernandez-Real, 2002, Blood letting in high-ferritin type 2 diabetes. Effects on insulin sensitivity and beta-cell function, Diabetes, 51, 1000, 10.2337/diabetes.51.4.1000 Valenti, 2007, Iron depletion by phlebotomy improves insulin resistance in patients with non-alcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study, Am J Gastroenterol, 102, 1251, 10.1111/j.1572-0241.2007.01192.x Kowdley, 2012, Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with non-alcoholic fatty liver disease, Hepatology, 55, 77, 10.1002/hep.24706 Zacharski, 2008, Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial, J Natl Cancer Inst, 100, 996, 10.1093/jnci/djn209